{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:29:57Z","timestamp":1772083797833,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005620","name":"North Carolina GlaxoSmithKline Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012781","name":"MSD K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.cllc.2018.11.012","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T14:10:41Z","timestamp":1543500641000},"page":"e362-e368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phase 1b\/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1016","volume":"20","author":[{"given":"Paul","family":"Wheatley-Price","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirish","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Dar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"George R.","family":"Blumenschein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2018.11.012_bib2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2217\/fon.14.275","article-title":"Diagnostic challenges in non\u2013small-cell lung cancer: an integrated medicine approach","volume":"11","author":"Salgia","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.cllc.2018.11.012_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cytogfr.2004.03.007","article-title":"The PDGF family: four gene products form five dimeric isoforms","volume":"15","author":"Fredriksson","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"issue":"15 pt 2","key":"10.1016\/j.cllc.2018.11.012_bib4","doi-asserted-by":"crossref","first-page":"s4632","DOI":"10.1158\/1078-0432.CCR-07-0212","article-title":"Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations","volume":"13","author":"Bauman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2018.11.012_bib5","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1124\/mol.112.084079","article-title":"Inhibition of PDGFR-alpha by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non\u2013small cell lung cancer","volume":"83","author":"Laing","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.cllc.2018.11.012_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1359-6349(10)71805-X","article-title":"Inhibition of PDGFR\u03b1 in tumor stroma with MEDI-575 enhances activity of carboplatin\/paclitaxel and delays tumor regrowth in a NSCLC xenograft model [abstract 100]","volume":"8","author":"Steiner","year":"2010","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.cllc.2018.11.012_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11060-016-2287-6","article-title":"Phase II study of MEDI-575, an anti\u2013platelet-derived growth factor-\u03b1 antibody, in patients with recurrent glioblastoma","volume":"131","author":"Phuphanich","year":"2017","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.cllc.2018.11.012_bib8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00280-015-2832-6","article-title":"A\u00a0phase I study of MEDI-575, a PDGFRalpha monoclonal antibody, in Japanese patients with advanced solid tumors","volume":"76","author":"Murakami","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cllc.2018.11.012_bib9","series-title":"Lartruvo [package insert]","year":"2017"},{"key":"10.1016\/j.cllc.2018.11.012_bib10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","article-title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","volume":"388","author":"Tap","year":"2016","journal-title":"Lancet"},{"issue":"15 suppl","key":"10.1016\/j.cllc.2018.11.012_bib11","article-title":"Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations","volume":"34","author":"von Mehren","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418303085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418303085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:10:52Z","timestamp":1761505852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730418303085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1525730418303085"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2018.11.012","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1b\/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non\u2013Small-Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2018.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}